Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 145 points (0.8%) at 17,506 as of Tuesday, Feb. 3, 2015, 12:10 PM ET. The NYSE advances/declines ratio sits at 2,277 issues advancing vs. 741 declining with 132 unchanged.

The Health Services industry currently is unchanged today versus the S&P 500, which is up 0.5%. A company within the industry that fell today was Baxter International ( BAX), up 1.3%. Top gainers within the industry include Tenet Healthcare ( THC), up 2.9%, Agilent Technologies ( A), up 1.1% and Medtronic ( MDT), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. WuXi PharmaTech (Cayman ( WX) is one of the companies pushing the Health Services industry lower today. As of noon trading, WuXi PharmaTech (Cayman is down $1.59 (-3.9%) to $38.79 on average volume. Thus far, 154,970 shares of WuXi PharmaTech (Cayman exchanged hands as compared to its average daily volume of 344,100 shares. The stock has ranged in price between $38.64-$40.38 after having opened the day at $40.12 as compared to the previous trading day's close of $40.38.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

WuXi PharmaTech (Cayman) Inc. operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company in China and the United States. It operates in two segments, Laboratory Services and Manufacturing Services. WuXi PharmaTech (Cayman has a market cap of $2.8 billion and is part of the health care sector. Shares are up 19.9% year-to-date as of the close of trading on Monday. Currently there are 4 analysts that rate WuXi PharmaTech (Cayman a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates WuXi PharmaTech (Cayman as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full WuXi PharmaTech (Cayman Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Opko Health ( OPK) is down $0.75 (-5.9%) to $11.88 on heavy volume. Thus far, 4.7 million shares of Opko Health exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $11.70-$12.74 after having opened the day at $12.70 as compared to the previous trading day's close of $12.63.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Opko Health has a market cap of $5.3 billion and is part of the health care sector. Shares are up 26.4% year-to-date as of the close of trading on Monday. Currently there are 4 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and feeble growth in the company's earnings per share. Get the full Opko Health Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, HCA Holdings ( HCA) is down $1.58 (-2.2%) to $68.60 on heavy volume. Thus far, 4.3 million shares of HCA Holdings exchanged hands as compared to its average daily volume of 5.3 million shares. The stock has ranged in price between $67.49-$69.94 after having opened the day at $67.74 as compared to the previous trading day's close of $70.18.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

HCA Holdings, Inc., through its subsidiaries, provides health care services. HCA Holdings has a market cap of $30.7 billion and is part of the health care sector. Shares are down 4.4% year-to-date as of the close of trading on Monday. Currently there are 16 analysts that rate HCA Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates HCA Holdings as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, revenue growth, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full HCA Holdings Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null